Preliminary agenda (subject to change)
| 8.15 | Registration and breakfast |
| 8.55 | Opening remarks Tuukka Hirvonen, Communications Manager - IR & Financial Communications |
| 9.00 | CEO's presentation Timo Lappalainen, President & CEO |
| R&D pipeline review, part I Reijo Salonen, SVP Research & Development | |
| 10.00 | Break |
| 10.15 | Proprietary Products update Markku Huhta-Koivisto, SVP Proprietary Products |
| Specialty Products update Liisa Hurme, SVP Specialty Products | |
| CFO's presentation Jari Karlson, CFO | |
| 11.35 | Break |
| 11.45 | Animal Health Niclas Lindstedt, Vice President |
| Fermion Arto Toivonen, President | |
| Orion Diagnostica Jaakko Rissanen, President | |
| R&D pipeline review, part II Reijo Salonen, SVP Research & Development | |
| 13.00 | Lunch and discussion with management |
| 14.30 | Event ends |
The presentations can also be followed through live webcast at www.orion.fi/en/investors. The presentation materials will be available on Orion website during the day and recordings of the presentations latest on the following day.
Please register to the event by email: ir@orion.fi or by tel. +358 10 426 2169 / +358 10 426 2721 no later than on Friday 15 May 2015 at 3.00 p.m. EEST.
Participants should be prepared to present a photo ID on request.
We hope you and your colleagues will take the opportunity to participate, and we look forward to meeting you there.
Yours sincerely,
Timo Lappalainen
President and CEO
Travel and accommodation
In order to assist you, we have reserved a quota of hotel rooms at Hotel Scandic Park which is a short walking distance from the venue Finlandia Hall. The rate for single room is EUR 134 and for double room EUR 154 (check in on May 25, check out May 26). Please refer to booking reference ORI250515 when making your reservation.
Scandic Park Helsinki, Mannerheimintie 46
Tel: +358 9 47 371
E-mail: parkhelsinki@scandichotels.com
http://www.scandichotels.com/
Participants are kindly asked to book their own flights and arrange transportation from and to the airport. Please note that Orion does not cover any costs for travelling or accommodation.
For further information, please contact:
Tuukka Hirvonen, Communications Manager, tel. +358 10 426 2721 or tuukka.hirvonen@orion.fi
Publisher:
Orion Corporation
www.orion.fi/en
www.orion.fi/en/investors
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.